Attention Deficit Hyperactivity Disorder Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Drug ( Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate, Atomoxetine, Guanfacine, Clonidine, Bupropion ); Drug Type ( Stimulant, Non-stimulant ); Demographic ( Adult (Aged 18 and above), Children ); Distribution Channel ( Retail Pharmacy, Hospital Pharmacy )
Report Code: TIPRE00011775
| No. of Pages: 150
| Category: Medical Device
| Status: Upcoming
Attention deficit hyperactivity disorder (ADHD) is a chronic condition, including attention difficulty, hyperactivity, and impulsiveness. However, it usually begins in childhood and can persist into adulthood. It contributes to low self-esteem, troubled relationships, and difficulty at school or work. Its symptoms include limited attention and hyperactivity. Whereas, its treatments include medication and talk therapy.
The attention deficit hyperactivity disorder market is driving due to the government support, along with growing awareness among various parties. Moreover, increase in awareness about mental health among the general population and governments is expected to propel the ADHD market.
The "Attention Deficit Hyperactivity Disorder Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of attention deficit hyperactivity disorder market with detailed market segmentation by drug, drug type, demographic and distribution channel. The attention deficit hyperactivity disorder market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in attention deficit hyperactivity disorder market and offers key trends and opportunities in the market.
The attention deficit hyperactivity disorder market is segmented on the basis of drug, drug type, demographic and distribution channel. Based on drug, the market is segmented as amphetamine, methylphenidate, lisdexamfetamine, dexmethylphenidate, atomoxetine, guanfacine, clonidine and bupropion. On the basis of drug type, the market is categorized as stimulant and non-stimulant. On the basis of demographic, the market is categorized as adult (aged 18 and above) and children. On the basis distribution channel, the market is categorized as retail pharmacy and hospital pharmacy.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the attention deficit hyperactivity disorder market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The attention deficit hyperactivity disorder market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting attention deficit hyperactivity disorder market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the attention deficit hyperactivity disorder market in these regions.
Get more information on this report :
The report covers key developments in the attention deficit hyperactivity disorder market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from attention deficit hyperactivity disorder market are anticipated to have lucrative growth opportunities in the future with the rising demand for attention deficit hyperactivity disorder in the global market. Below mentioned is the list of few companies engaged in the attention deficit hyperactivity disorder market.
The report also includes the profiles of key players in attention deficit hyperactivity disorder market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Eli Lily & Company
Johnson & Johnson Services, LLC
NEOS Therapeutics Inc.
Prude Pharma L.P.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
The List of Companies
1. Eli Lily & Company
2. Johnson & Johnson Services, LLC
3. Lupin Limited
4. Mallinckrodt Pharmaceuticals
5. NEOS Therapeutics Inc.
7. Prude Pharma L.P.
8. Shire Plc